HR+/HER2- Advanced Breast Cancer:
Unmet Needs in 2L Treatment and ET Resistance
Program Objectives:
Review the unmet needs for patients with HR+/HER2- advanced breast cancer with disease progression on or after ET and CDK4/6i
Discuss the role of the PI3K/AKT/PTEN pathway in advanced breast cancer progression and ET resistance
Clinical Perspectives presented by:
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Paolo Tarantino, MD
Advanced Research Fellow
Dana-Farber Cancer Institute
Harvard Medical School
This program is sponsored by AstraZeneca and is intended for US healthcare professionals only.